




ACADEMIA ESPAÑOLA
DE DERMATOLOGÍA
Y VENEREOLÓGIA

ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



CASE AND RESEARCH LETTER

[Translated article] Use of a Spinal Cord Stimulator to Treat Livedoid Vasculopathy: Effective Control of an Untreatable Disease

Estimulador medular en la vasculopatía livedoide: control eficaz de una patología intratable

To the Editor,

Livedoid vasculopathy is a chronic thrombo-occlusive disease with significant skin involvement.¹ Due to its chronic nature, it poses a therapeutic challenge. Various treatment options have demonstrated their beneficial role in multiple studies.^{2,3} However, refractory cases can sometimes be difficult to manage, making the search for new therapeutic modalities relevant for disease control and symptomatic relief for patients.

This is the case of a 68-year-old woman under dermatological supervision with a 6-year history of lesion outbreaks on her legs that, both clinically and histologically, were consistent with livedoid vasculopathy (Fig. 1). Tests performed to rule out any associated disease, such as antiphospholipid syndrome, paraproteinemias, genetic prothrombotic disorders, rheumatologic and autoimmune diseases tested negative. The patient received multiple topical, oral, and parenteral drugs (pentoxifylline, acetylsalicylic acid, colchicine, nifedipine, bosentan, rivaroxaban, sildenafil, nitroglycerin, immunoglobulins, rituximab, and sevoflurane), which were eventually discontinued due to lack of response or intolerance. Additionally, she exhibited poor tolerance to different analgesics. Given the torpid and aggressive course of the condition, poor pain control, and skin involvement, she was referred to the Pain Unit, where she underwent spinal cord posterior column stimulation implant placement. The patient showed a marked improvement in pain and almost complete reso-

lution of the cutaneous ulcers, with a sustained response over the following months (Fig. 2).

Livedoid vasculopathy is a rare chronic skin disorder that impacts quality of life significantly. Clinical presentation is characterized by persistent, very painful ulcers that mainly affect the legs bilaterally. Additionally, patients display livedo racemosa and areas of atrophie blanche.¹ Diagnosis is histologically confirmed, including the presence of intraluminal thrombosis, endothelial proliferation, and subintimal hyaline degeneration of the dermal vasculature.⁴ After histopathological confirmation, associated systemic diseases such as primary antiphospholipid syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, or mixed connective tissue disease should be ruled out.⁵

Various treatment modalities often yield inconsistent results, requiring combined or sequential procedures, typically with low levels of evidence.^{2,3} On the one hand, it is important to implement general measures such as pain management, wound care, and compression therapy.^{3,4} On the other hand, therapeutic measures aimed at reducing the risk of thrombosis, such as antiplatelet agents, anticoagulants, and fibrinolytic agents, as well as immunomodulators and vasodilators, are used.³

The implantation of electrodes over the posterior spinal columns works through 2 mechanisms: centripetal inhibition, preventing the nerve impulse from the peripheral nerve endings to the central nervous system, which stops the pain sensation from becoming conscious; and centrifugal inhibition, preventing the creation of a sympathetic nerve impulse, promoting peripheral vasodilation and improving perfusion of distal areas, and reducing pain.^{6,7} In our patient, this translated into a satisfactory improvement of the ulcers and discomfort intensity. Its use in other vasculopathies has been documented in the literature, yet no cases of livedoid vasculopathy successfully treated with this modality have ever been published to this date.⁸ This technique is fairly safe, with complication incidence rates of 5.3% up to 40%.⁹ Among them, we find surgical infections^{7,9} (2.5% up to 10%) and mechanical complications such as migration (2.1% up to 27%) or breakage (0% up to 9.1%) of the wire, discomfort caused by the pulse generator (0.9-12%^{7,9}), and device malfunction (0% up to 10.2%).⁹ The most serious complication is neurological damage (0.4% up to 2.1%¹⁰), which may include the development of epidural hematoma (0.3%), major neurological deficit (0.25%), lim-

DOI of original article:

<https://doi.org/10.1016/j.ad.2023.02.037>

<https://doi.org/10.1016/j.ad.2024.09.008>

0001-7310/© 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: L. Revelles-Peñas, S. Pastor-Navarro, A.A. López-Piñero et al., [Translated article] Use of a Spinal Cord Stimulator to Treat Livedoid Vasculopathy: Effective Control of an Untreatable Disease, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.09.008>



Figure 1 Livedoid vasculopathy lesions affecting the lower limbs. Livedoid changes, atrophie blanche, and fibrinoid ulcers can be observed.



Figure 2 Livedoid vasculopathy lesions 1 month after spinal cord posterior column stimulation implant. Ulcer healing and improvement of livedoid changes are observed. Additionally, pain control was achieved.

ited motor deficit (0.1%), autonomic changes (0.013%), or sensory deficit (0.1%).⁹ However, these rates have dropped due to technological advancements and improved implantation techniques.⁹

The formation of an epidural hematoma is rare, primarily occurring after surgical device insertion, and sometimes resulting in permanent neurological damage. This risk is increased in patients on antiplatelet or anticoagulant ther-

apy, so clinical practice guidelines exist to prevent it. Since the incidence of epidural hematomas in patients on anti-coagulant or antiplatelet therapy is unknown, management must be individualized.¹⁰

Posterior column stimulation can be considered an alternative when treating patients with livedoid vasculopathy who remain unresponsive to other more traditional options.

References

1. Bologna JL, Jorizzo JL, Schaffer JV. *Dermatology*. 3rd ed. Reino Unido: Elsevier Saunders; 2012.
2. Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: A review of pathogenesis and principles of management. *Indian J Dermatol Venereol Leprol*. 2016;82:478–88.
3. Bilgic A, Ozcobanoglu S, Bozca BC, Alpsoy E. Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management. *Int J Womens Dermatol*. 2021;7:588–99.
4. Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR, et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. *J Am Acad Dermatol*. 2013;69:1033–42.e1.
5. Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. *Br J Dermatol*. 1989;120:419–29.
6. Caylor J, Reddy R, Yin S, Cui C, Huang M, Huang C, et al. Spinal cord stimulation in chronic pain: evidence and theory for mechanisms of action. *Bioelectron Med*. 2019;5:12.
7. Tapia Pérez JH. Estimulación de la médula espinal: más allá del manejo del dolor. *Neurología*. 2022;37:586–95.
8. Horsch S, Claeys L. Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease. *Ann Vasc Surg*. 1994;8:468–74.
9. Eldabe S, Buchser E, Duarte RV. Complications of Spinal Cord Stimulation and Peripheral Nerve Stimulation Techniques: A Review of the Literature. *Pain Med*. 2016;17:325–36.
10. Narouze S, Benzon HT, Provenzano DA, Buvanendran A, De Andres J, Deer TR, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. *Reg Anesth Pain Med*. 2015;40:182–2012.

L. Revelles-Peñas^{a,*}, S. Pastor-Navarro^b,
A.A. López-Piñero^c, V. Velasco-Tirado^a

^a *Departamento de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain*

^b *Departamento de Reumatología, Hospital Universitario de Salamanca, Salamanca, Spain*

^c *Departamento de Anestesiología y Reanimación, Hospital Universitario de Salamanca, Salamanca, Spain*

* Corresponding author.

E-mail address: leonor_lrp@hotmail.com

(L. Revelles-Peñas).